Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENYATTA: Astegolimab in Uncontrolled Severe Asthma
NCT02918019Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Apr 2019
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial of astegolimab in asthma (4 arms), sponsored by Roche. Primary endpoint: Annualized Asthma Exacerbation Rate at 54 weeks. Started Sep 2016; status: completed.
02
Drugs
astegolimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02918019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918019.